MX2022002537A - Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas. - Google Patents
Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas.Info
- Publication number
- MX2022002537A MX2022002537A MX2022002537A MX2022002537A MX2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A MX 2022002537 A MX2022002537 A MX 2022002537A
- Authority
- MX
- Mexico
- Prior art keywords
- bacterial infections
- beta
- treating bacterial
- orally administered
- avibactam
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893612P | 2019-08-29 | 2019-08-29 | |
| US201962953852P | 2019-12-26 | 2019-12-26 | |
| PCT/US2020/048119 WO2021041616A1 (en) | 2019-08-29 | 2020-08-27 | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002537A true MX2022002537A (es) | 2022-03-22 |
Family
ID=72433031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002537A MX2022002537A (es) | 2019-08-29 | 2020-08-27 | Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20210060033A1 (enExample) |
| EP (1) | EP4021443A1 (enExample) |
| JP (1) | JP7673052B2 (enExample) |
| KR (1) | KR20220054364A (enExample) |
| CN (1) | CN114302725A (enExample) |
| AU (2) | AU2020337449A1 (enExample) |
| BR (1) | BR112022001344A2 (enExample) |
| CA (1) | CA3152300C (enExample) |
| IL (1) | IL290260A (enExample) |
| MX (1) | MX2022002537A (enExample) |
| WO (1) | WO2021041616A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| EP4319760A4 (en) * | 2021-04-05 | 2025-01-08 | Qpex Biopharma, Inc. | CEFTIBUTENE DOSAGE REGIMEN |
| JP2024524372A (ja) * | 2021-07-01 | 2024-07-05 | キューペックス バイオファーマ， インコーポレイテッド | セフチブテンの結晶形態 |
| US20240390335A1 (en) * | 2021-11-09 | 2024-11-28 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Pharmaceutical composition containing beta-lactam compound and use thereof |
| CN115448920B (zh) * | 2022-10-14 | 2025-01-03 | 广州楷石医药有限公司 | 一种β-内酰胺酶抑制剂及其应用 |
| CN116327764B (zh) * | 2023-04-06 | 2024-04-12 | 浙江医药股份有限公司新昌制药厂 | 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用 |
| CN119431373B (zh) * | 2024-07-24 | 2025-08-08 | 科睿迪(南京)医药科技有限公司 | 一种β-内酰胺酶抑制剂及其用途 |
| CN122079989A (zh) * | 2024-09-30 | 2026-05-26 | 科睿迪(南京)医药科技有限公司 | 二氮杂二环类β-内酰胺酶抑制剂及其应用 |
| WO2026104587A1 (en) | 2024-11-13 | 2026-05-21 | Adjutec Pharma As | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016046845A1 (en) * | 2014-09-25 | 2016-03-31 | Manu Chaudhary | Stealth, targeted nanoparticles (stn) for oral drug delivery |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| MX2020004071A (es) | 2017-10-02 | 2020-07-28 | Arixa Pharmaceuticals Inc | Derivados de aztreonam y usos de los mismos. |
-
2020
- 2020-08-27 EP EP20768776.5A patent/EP4021443A1/en active Pending
- 2020-08-27 JP JP2022512720A patent/JP7673052B2/ja active Active
- 2020-08-27 KR KR1020227010180A patent/KR20220054364A/ko not_active Ceased
- 2020-08-27 MX MX2022002537A patent/MX2022002537A/es unknown
- 2020-08-27 WO PCT/US2020/048119 patent/WO2021041616A1/en not_active Ceased
- 2020-08-27 US US17/004,409 patent/US20210060033A1/en not_active Abandoned
- 2020-08-27 BR BR112022001344A patent/BR112022001344A2/pt unknown
- 2020-08-27 CN CN202080060861.2A patent/CN114302725A/zh active Pending
- 2020-08-27 AU AU2020337449A patent/AU2020337449A1/en not_active Abandoned
- 2020-08-27 CA CA3152300A patent/CA3152300C/en active Active
-
2022
- 2022-01-31 IL IL290260A patent/IL290260A/en unknown
-
2023
- 2023-03-13 US US18/182,675 patent/US20230210863A1/en not_active Abandoned
-
2024
- 2024-03-22 AU AU2024201877A patent/AU2024201877B2/en active Active
-
2025
- 2025-04-17 US US19/182,251 patent/US20260158040A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220054364A (ko) | 2022-05-02 |
| EP4021443A1 (en) | 2022-07-06 |
| WO2021041616A1 (en) | 2021-03-04 |
| US20230210863A1 (en) | 2023-07-06 |
| US20210060033A1 (en) | 2021-03-04 |
| US20260158040A1 (en) | 2026-06-11 |
| CA3152300C (en) | 2024-04-30 |
| BR112022001344A2 (pt) | 2022-06-07 |
| AU2024201877A1 (en) | 2024-04-11 |
| AU2024201877B2 (en) | 2025-05-08 |
| CA3152300A1 (en) | 2021-03-04 |
| JP7673052B2 (ja) | 2025-05-08 |
| IL290260A (en) | 2022-04-01 |
| CN114302725A (zh) | 2022-04-08 |
| AU2020337449A1 (en) | 2022-03-03 |
| JP2022545291A (ja) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001344A2 (pt) | Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas | |
| JOP20220130A1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| MX2019013260A (es) | Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas. | |
| WO2023205463A8 (en) | Heteroaryl compounds for the treatment of pain | |
| CR20240514A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| CL2021000176A1 (es) | Uso de especies gram negativas para tratar la dermatitis atópica | |
| EP4591874A3 (en) | Pharmaceutical development | |
| MX2024008221A (es) | Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico. | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| ECSP23080267A (es) | Compuestos de lactivicina, su preparación y uso como agentes antibacterianos | |
| MX2022006109A (es) | Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa. | |
| WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| CA3155674A1 (en) | Pimobendan formulation and method of use thereof | |
| MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
| AR120862A1 (es) | Combinaciones de amoxicilina y derivados de avibactam administrados oralmente para tratar infecciones micobacterianas | |
| RU2018113229A (ru) | Терапия антибиотиками | |
| AR126757A1 (es) | Uso de un derivado de la ciclohexanetriona y de una composición farmacéutica que lo comprende en la preparación de medicamentos para animales | |
| AR045564A1 (es) | Forma de dosificacion en forma de multiples particulas, formulada mediante fusion . preparado de combinacion farmaceutica | |
| UY28340A1 (es) | Profármaco inhibidor de beta-lactamasa | |
| IT202300013884A1 (it) | Composizione per la somministrazione orale per prevenire e trattare cefalea ed emicrania. | |
| WO2023004188A3 (en) | Inhibiting intracellular pathogens | |
| WO2024231881A3 (en) | Polymorphic forms and formulations of leriglitazone | |
| WO2022216852A3 (en) | Pharmaceutical compositions for treating diseases |